|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:DNA-dependent_DNA_polymerase
|
|
gptkbp:activities
|
nucleotide reverse transcriptase inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
oral solution
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
adults
|
|
gptkbp:brand
|
gptkb:Viread
|
|
gptkbp:can_be_used_with
|
other antiretrovirals
|
|
gptkbp:clinical_trial
|
25% to 30%
Phase III
|
|
gptkbp:contraindication
|
none known
hypersensitivity
renal impairment
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dosage_form
|
gptkb:tablet
gptkb:item
oral tablet
|
|
gptkbp:excretion
|
urine
unchanged in urine
|
|
gptkbp:formulation
|
gptkb:tenofovir_alafenamide
gptkb:tenofovir_disoproxil_fumarate
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tenofovir
|
|
gptkbp:indication
|
gptkb:post-exposure_prophylaxis_(PEP)
pre-exposure prophylaxis (Pr EP)
|
|
gptkbp:ingredients
|
C23 H31 N5 O8 P
|
|
gptkbp:interacts_with
|
gptkb:atazanavir
gptkb:ritonavir
gptkb:efavirenz
gptkb:lamivudine
gptkb:emtricitabine
other nephrotoxic drugs
|
|
gptkbp:invention
|
gptkb:2021
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
HIV treatment
hepatitis B treatment
|
|
gptkbp:lifespan
|
17 hours
about 17 hours
|
|
gptkbp:marketed_as
|
gptkb:Viread
gptkb:Atripla
gptkb:Biktarvy
gptkb:Descovy
|
|
gptkbp:metabolism
|
kidney
minimal hepatic metabolism
|
|
gptkbp:research_areas
|
gptkb:chronic_hepatitis_B
HIV prevention
|
|
gptkbp:rounds
|
urine
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
bone density loss
kidney toxicity
|